IN THE UNITE STATES PATENT AND TRAD. JARK OFFICE

Applicants:

Elazar Rabbanı et al

Serial No.

08/978,635

Filed:

November 25, 1997

Title

NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USE Group Art Unit. 1635

Examiner Mary M. Schmidt

idt HAUHMANNES

527 Madison Avenue, 9th Floor New York, New York 10022 August 16, 1999

FILED VIA FIRST CLASS MAIL

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Attention: Box Sequence

SECOND AMENDMENT IN CONNECTION WITH NOTICE
TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES UNDER 37 C.F.R. §§1.821-1.825

Dear Sirs:

Pursuant to the Office Action issued February 16, 1999 in connection with the instant application wherein a Raw Sequence Listing Error Report was attached, Applicants are submitting this Second Amendment in connection with the Amendment In Connection With Notice to Comply with Sequence Rules filed on June 8, 1998.

PLEASE AMEND THIS APPLICATION AS FOLLOWS:

In the Specification:

Page 23, after the last paragraph, kindly replace the sequence listing with the attached 13 pages inserted directly after this page and before page 24.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Pottal Service as first class mail in an envelope addressed to Commissioner of Patents & Trademarks Washington.

DTC 20231

Ronald C. Fedus Reg. No. 32567 ---

ENZ-53(D4)